Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

This study has been completed.
Information provided by:
Protein Sciences Corporation Identifier:
First received: October 30, 2006
Last updated: December 16, 2009
Last verified: December 2009